

**Amendments to the Claims**

1.-22. (canceled).

23. (currently amended): [[A]] The method according to claim [[22]] 36 wherein said protein is selected from the group comprising enzymes, antibodies, antigens, hormones and cytokines.

24. (currently amended): [[A]] The method according to claim 23 wherein said therapeutically active protein is a hormone.

25. (currently amended): [[A]] The method according to claim 24 wherein said hormone is insulin.

26. (currently amended): [[A]] The method according to claim 23 wherein said protein is a cytokine.

27. (currently amended): [[A]] The method according to claim 26 wherein said cytokine is Factor VIII.

28. (currently amended): [[A]] The method according to claim [[22]] 36 wherein the particle size of said protein is from about 0.01  $[\mu]$   $\mu\text{m}$  to about 10.0  $[\mu]$   $\mu\text{m}$ .

29. (currently amended): [[A]] The method according to claim 28 wherein the particle size of said protein is from about  $[[5.0 \mu]]$  0.01  $\mu\text{m}$  to about  $[[10.0 \mu]]$  5.0  $\mu\text{m}$ .

30. (currently amended): [[A]] The method according to claim 29 wherein the particle size of said protein is from about 0.01  $[\mu]$   $\mu\text{m}$  to about 3.0  $[\mu]$   $\mu\text{m}$ .

Serial No. 10/020,798

31.–35. (canceled).

36. (new): A method for delivering a therapeutically active protein to the respiratory tract of a patient in need of treatment comprising the steps of:

- a) preparing a liquid carrier vehicle consisting essentially of:
  - i) about 100% v/v substantially anhydrous ethanol; and
  - ii) from about 0.05% to about 5.0 w/v of a pharmaceutically acceptable excipient;
- b) suspending a pharmaceutically effective amount of said protein in said liquid carrier vehicle to produce a suspension;
- c) producing an aerosol of said suspension using an electrohydrodynamic spraying/aerosolization means; and
- d) administering said aerosol to the pulmonary tract of said patient via inhalation of said aerosol.

37. (new): The method according to claim 36 wherein said substantially anhydrous ethanol contains less than 3.0% v/v water.

38. (new): The method according to claim 25 wherein said insulin is present in the suspension at a concentration of from about 1.0 mg/ml to about 200.0 mg/ml of said suspension.

39. (new): The method according to claim 38 wherein the particle size of said insulin is from about 0.01  $\mu\text{m}$  to about 5.0  $\mu\text{m}$ .

Serial No. 10/020,798

40. (new): The method according to claim 36 wherein said pharmaceutically acceptable excipient is present in said liquid carrier at from about 0.05% w/v to about 5.0% w/v of said carrier.

41. (new): The method according to claim 40 wherein said pharmaceutically acceptable excipient is a suspending agent.